Chief Operating Officer

Chris White is an industry veteran with over 30 years of experience in the biopharmaceutical industry. His expertise includes operations management, business development, commercial planning, and strategy creation/implementation. Mr. White was recently Chief Business Officer at Entasis Therapeutics, a venture-backed biotech company focused on developing novel antibiotics. At Entasis, he led commercial planning, business development, and fundraising activities. Prior to Entasis, Mr. White held the position of Chief Business Officer at AMAG Pharmaceuticals, where he was responsible for establishing several partnerships, including creating a licensing, development, and commercialization agreement with Takeda valued at up to $280 million. He also expanded AMAG’s commercial portfolio by in-licensing oral mucositis product MuGard from Access Pharmaceuticals. Before joining AMAG, Mr. White spent 13 years as a management consultant, including partner-level positions at consulting firms A.T. Kearney and Accenture. Earlier in his career, he was employed at Merck’s U.S. Human Health group, where he led Merck’s strategic planning activities and served as product manager in the hospital products group. Mr. White began his career in the pharmaceutical industry as a sales representative with DuPont Pharmaceuticals. He holds a B.S. in Chemical Engineering from Tufts University and an MBA from Columbia University’s Graduate School of Business.

Chief Medical Officer

Ross Breckenridge is a recognized leader in cardiovascular medicine with specific expertise on the heart’s response to low levels of oxygen and identifying novel therapeutic targets for heart disease. In addition, Dr. Breckenridge has 15 years of experience as a consultant to investment funds. He currently sits on the Board of Directors of REVA Medical. Dr. Breckenridge studied Medical Sciences at Cambridge University, then qualified in clinical medicine from Oxford University Medical School. He completed a PhD in cardiac development at the Wellcome/CRUK Institute at Cambridge and went on to train in Clinical Pharmacology at University College London, where he was previously a consultant physician and Director of the London Clinical Pharmacology Training Programme.